Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.21. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| BIO | USIG | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Fixed Income |
52-Week High | $356.25 | $52.69 |
52-Week Low | $241.71 | $50.18 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USIG trades at $50.40 with minimal daily movement (+0.16%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The company maintains consistent dividend distributions, with recent payouts of $0.20-$0.21 per share. Recent news includes AM Best affirming credit ratings for subsidiaries following a transaction with Tiptree Inc.
Investment outlook remains cautious given bearish technical signals and limited fundamental data availability. The steady dividend history provides income appeal, but investors face uncertainty from incomplete financial metrics. Key risks include potential volatility from institutional positioning changes and transaction integration challenges with Tiptree.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
